Conditions: Acute Coronary Syndrome
Keywords: Atherosclerosis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 52
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine the effect of VIA-2291 as compared to placebo on vascular inflammation following 24 weeks of dosing.

Detailed description:
The effect of VIA-2291 on vascular inflammation will be assessed through 18FDG PET vascular imaging measurements and various biomarkers after 24 weeks.

Arms:
arm 1: VIA-2291 100mg arm 2: Matching placebo

Interventions: intervention 1: VIA-2291 intervention 2: Placebo
Intervention descriptions: intervention 1: 100 mg, oral dosing, 1 time daily for 24 weeks intervention 2: oral dosing, 1 time daily for 24 weeks

Protocol document: